Anita Mamtani1, Varadan Sevilimedu2, Tiana Le1, Monica Morrow1, Andrea V Barrio1. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: In early studies, local recurrence (LR) rates were higher after neoadjuvant chemotherapy (NAC) in comparison with upfront surgery. Modern outcomes are uncertain, particularly among those who are initially breast-conserving surgery-ineligible (BCSi) and downstage to being breast-conserving surgery-eligible (BCSe). METHODS: Among patients with cT1-3 breast cancer treated from 2014 to 2018 who were BCSe after NAC, clinicopathologic characteristics and LR were compared between initially BCSe patients and BCSi patients who downstaged. Breast-conserving surgery (BCS) eligibility was determined prospectively. RESULTS: Among 685 patients, 243 (35%) were BCSe before and after NAC and had BCS; 282 (41%) were BCSi before NAC, downstaged to BCSe, and had BCS; and 160 (23%) were BCSi before NAC, downstaged to BCSe, and chose mastectomy. The median age was 52 years, and most cancers were cT1-2 (84%), cN+ (61%), and human epidermal growth factor receptor 2-positive (HER2+; 38%) or triple-negative (34%). Those who were BCSe before NAC had a lower cT stage, whereas those who chose mastectomy were younger (P < .05). NAC was usually ACT (doxorubicin, cyclophosphamide, and a taxane)-based (92%), 99% of HER2+ patients received dual blockade, and 99% of BCS patients received adjuvant radiation. At a median follow-up of 35 months, 22 patients (3.2%) had developed LR. The Kaplan-Meier 4-year LR rates were not different among the groups (1.9% for those who were BCSe before and after NAC, 6.3% for those who downstaged to being BCSe and underwent BCS, and 2.7% for those who downstaged and underwent mastectomy; P = .17). CONCLUSIONS: LR rates are low after NAC and BCS, even among BCSi patients who downstage, and they are not improved in patients who downstage and choose mastectomy. Mastectomy can be safely avoided in BCSi patients who downstage with NAC.
BACKGROUND: In early studies, local recurrence (LR) rates were higher after neoadjuvant chemotherapy (NAC) in comparison with upfront surgery. Modern outcomes are uncertain, particularly among those who are initially breast-conserving surgery-ineligible (BCSi) and downstage to being breast-conserving surgery-eligible (BCSe). METHODS: Among patients with cT1-3 breast cancer treated from 2014 to 2018 who were BCSe after NAC, clinicopathologic characteristics and LR were compared between initially BCSe patients and BCSi patients who downstaged. Breast-conserving surgery (BCS) eligibility was determined prospectively. RESULTS: Among 685 patients, 243 (35%) were BCSe before and after NAC and had BCS; 282 (41%) were BCSi before NAC, downstaged to BCSe, and had BCS; and 160 (23%) were BCSi before NAC, downstaged to BCSe, and chose mastectomy. The median age was 52 years, and most cancers were cT1-2 (84%), cN+ (61%), and human epidermal growth factor receptor 2-positive (HER2+; 38%) or triple-negative (34%). Those who were BCSe before NAC had a lower cT stage, whereas those who chose mastectomy were younger (P < .05). NAC was usually ACT (doxorubicin, cyclophosphamide, and a taxane)-based (92%), 99% of HER2+ patients received dual blockade, and 99% of BCS patients received adjuvant radiation. At a median follow-up of 35 months, 22 patients (3.2%) had developed LR. The Kaplan-Meier 4-year LR rates were not different among the groups (1.9% for those who were BCSe before and after NAC, 6.3% for those who downstaged to being BCSe and underwent BCS, and 2.7% for those who downstaged and underwent mastectomy; P = .17). CONCLUSIONS: LR rates are low after NAC and BCS, even among BCSi patients who downstage, and they are not improved in patients who downstage and choose mastectomy. Mastectomy can be safely avoided in BCSi patients who downstage with NAC.
Authors: Shannon K Swisher; Jose Vila; Susan L Tucker; Isabelle Bedrosian; Simona F Shaitelman; Jennifer K Litton; Benjamin D Smith; Abigail S Caudle; Henry M Kuerer; Elizabeth A Mittendorf Journal: Ann Surg Oncol Date: 2015-10-28 Impact factor: 5.344
Authors: Irene L Wapnir; Stewart J Anderson; Eleftherios P Mamounas; Charles E Geyer; Jong-Hyeon Jeong; Elizabeth Tan-Chiu; Bernard Fisher; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Antonios Valachis; Eleftherios P Mamounas; Elizabeth A Mittendorf; Naoki Hayashi; Makoto Ishitobi; Clara Natoli; Florian Fitzal; Isabel T Rubio; Daniel G Tiezzi; Hee-Chul Shin; Stewart J Anderson; Kelly K Hunt; Naoko Matsuda; Shozo Ohsumi; Athina Totomi; Cecilia Nilsson Journal: Cancer Date: 2018-05-03 Impact factor: 6.860
Authors: B Fisher; J Bryant; N Wolmark; E Mamounas; A Brown; E R Fisher; D L Wickerham; M Begovic; A DeCillis; A Robidoux; R G Margolese; A B Cruz; J L Hoehn; A W Lees; N V Dimitrov; H D Bear Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Allen M Chen; Funda Meric-Bernstam; Kelly K Hunt; Howard D Thames; Mary Jane Oswald; Elesyia D Outlaw; Eric A Strom; Marsha D McNeese; Henry M Kuerer; Merrick I Ross; S Eva Singletary; Fredrick C Ames; Barry W Feig; Aysegul A Sahin; George H Perkins; Naomi R Schechter; Gabriel N Hortobagyi; Thomas A Buchholz Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Johanna G H van Nes; Hein Putter; Jean-Pierre Julien; Michelle Tubiana-Hulin; Marc van de Vijver; Jan Bogaerts; Monika de Vos; Cornelis J H van de Velde Journal: Breast Cancer Res Treat Date: 2008-05-18 Impact factor: 4.872
Authors: Stewart J Anderson; Irene Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Jong-Hyeon Jeong; Charles E Geyer; D Lawrence Wickerham; Joseph P Costantino; Norman Wolmark Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544